Health Catalyst (HCAT) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $70.5 million, exceeding guidance of $68 million to $70 million.

Technology Revenue: $48.8 million.

Professional Services Revenue: $21.7 million.

Adjusted Gross Margin: 51%, up from 50% year-over-year.

Adjusted EBITDA: $9.9 million, at the high end of the guidance range ($9 million to $10 million).

Adjusted Net Income per Share: $0.04, with a weighted average share count of 74 million.

Cash Position: Approximately $103.4 million, slightly down from Q1 but still higher than the previous year.

2Strategic Updates and Business Highlights

Vitalware Divestiture: Closed on July 31, 2026, for $147 million, allowing HCAT to fully repay approximately $160 million in credit facility debt, eliminating about $19 million in annual interest expenses.

Project Nexus: Ongoing strategic initiative aimed at transforming the operating model and repositioning the business. Early signs of success with bookings tracking as anticipated.

Focus Areas: Concentrating on core technology opportunities and improving operational efficiencies while navigating the challenges faced by health systems.

3Forward Guidance and Outlook

Full Year 2026 Revenue Guidance: Updated to $246 million to $249 million, reflecting the removal of Vitalware's contributions.

Adjusted EBITDA Guidance: Revised to $18 million to $18.5 million.

Q3 2026 Revenue Guidance: Expected to be between $55 million and $56 million, with adjusted EBITDA projected to be breakeven to $500,000.

Long-Term Vision: Continued investment in technology and talent, with a focus on creating sustainable value.

4Bad News, Challenges, or Points of Concern

Revenue Headwinds: Ongoing challenges related to platform migrations and lower-margin services work, contributing to churn dynamics.

Migration-Related Churn: Noted $12.5 million of notified ARR down-sell and identified $52 million of additional at-risk ARR, with significant pressure on retention.

Gross Margin Impact: Expectation that adjusted gross margin will fall below 50% for the full year due to the removal of higher-margin Vitalware business.

Competitive Pressures: The RCM market is becoming increasingly competitive, necessitating significant investment for growth.

5Notable Q&A Insights

Divestiture Impact: The removal of Vitalware significantly influenced the updated guidance, with both revenue and EBITDA projections reflecting this change.

Future Divestitures: Management indicated a focus on core business fundamentals rather than pursuing additional divestitures at this time.

Investment Strategy: Emphasis on validating high-conviction opportunities and retaining talent during the ongoing transformation was highlighted. Overall, Health Catalyst is navigating a significant transformation while addressing immediate challenges, focusing on long-term growth and operational efficiency.